文献速递临床试验与 GCP

环泊酚用于椎管内麻醉辅助镇静:随机对照试验方案

Cipepofol for adjunctive sedation during neuraxial anesthesia: a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2026-05-21

本研究为随机、双盲、非劣效性试验,拟将接受椎管内麻醉的患者按1:1随机分配至环泊酚组或丙泊酚组,比较辅助镇静成功率。环泊酚组给予0.1 mg/kg负荷量后以0.3 mg/kg/h起始维持,丙泊酚组给予0.5 mg/kg负荷量后以1.5 mg/kg/h起始维持,目标镇静深度为MOAA/S评分3-4分。主要结局为镇静成功率,次要结局涵盖MOAA/S维持时间百分比、起效时间、补救镇静比例、生命体征、药物调整次数与总用量、恢复时间、PACU停留及满意度等。

要点

  • 环泊酚组负荷量0.1 mg/kg,维持起始0.3 mg/kg/h;丙泊酚组负荷量0.5 mg/kg,维持起始1.5 mg/kg/h。
  • 目标镇静深度为MOAA/S评分3-4分,主要结局为镇静成功率。
  • 试验为随机双盲非劣效性设计,已在ChiCTR注册(ChiCTR2500102635)。

核心结论

  • 该方案旨在评估环泊酚用于椎管内麻醉辅助镇静的有效性与安全性,若效果不劣于丙泊酚则可作为临床替代选择。

研究设计与样本

  • 随机、双盲、非劣效性试验,符合条件患者按1:1比例经随机数字表分配至环泊酚组或丙泊酚组。

主要发现

  • 主要结局为镇静成功率;次要结局包括MOAA/S维持3-4分、1-2分或5分的时间百分比。
  • 次要结局还包括负荷量开始至首次MOAA/S<4的时间及3分钟内达到MOAA/S<4的受试者比例。
  • 次要结局涵盖需补救镇静的比例、生命体征、剂量调整次数与总镇静药消耗量。
  • 次要结局包括停药至术后首次MOAA/S=5的时间、PACU停留时间及出PACU时恢复状态。
  • 次要结局包括麻醉医师、外科医师及受试者的满意度。

关键数值与推荐

  • 环泊酚组静脉负荷量0.1 mg/kg,30±10秒内给予,随后以0.3 mg/kg/h起始持续输注以达到目标镇静水平。
  • 丙泊酚组静脉负荷量0.5 mg/kg,30±10秒内给予,随后以1.5 mg/kg/h起始持续输注。
  • 目标镇静水平定义为MOAA/S评分3-4分。

临床怎么用

  • 若环泊酚在椎管内麻醉辅助镇静中表现与丙泊酚相当,可作为临床可选的镇静药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cipepofol is a novel 2,6-disubstituted phenol derivative increasingly used for anesthesia and sedation during gastrointestinal endoscopy and fiberoptic bronchoscopy. This study aimed to evaluate the efficacy and safety of cipepofol for adjunctive sedation during neuraxial anesthesia, thereby providing evidence for its clinical application. METHODS: This was a randomized, double-blind, non-inferiority trial. Eligible patients were randomly assigned in a 1:1 ratio to either the cipepofol group or the propofol group using a random number table. The target sedation level was defined as a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score of 3-4. Patients allocated to the cipepofol group received an intravenous loading dose of 0.1 mg/kg cipepofol administered over 30 ± 10 s, followed by a continuous infusion initiated at 0.3 mg/kg/h to achieve the target sedation level. Those in the propofol group received an intravenous loading dose of 0.5 mg/kg propofol administered over 30 ± 10 s, followed by a continuous infusion initiated at 1.5 mg/kg/h. The primary outcome was the sedation success rate. Secondary outcomes included the following: the percentage of total study drug administration time during which MOAA/S scores were maintained at 3-4, 1-2, or 5, respectively; time from the start of the intravenous loading dose to the first occurrence of MOAA/S score < 4, and the proportion of subjects achieving MOAA/S score < 4 within 3 min; proportion of subjects requiring rescue sedation; the vital signs of subjects; number of dose adjustments and total sedative drug consumption; time from discontinuation of the study drug infusion to the first postoperative MOAA/S score of 5, length of stay in the post-anesthesia care unit (PACU), and recovery status at PACU discharge; satisfaction levels of the anesthesiologist, surgeon, and subjects. DISCUSSION: The purpose of this study is to evaluate the efficacy and safety of cipepofol as an adjunct sedative during neuraxial anesthesia. If cipepofol demonstrates beneficial properties comparable to propofol for adjunctive sedation during neuraxial anesthesia, it could serve as a viable clinical alternative. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2500102635. Registered on 16 May 2025, www.chictr.org.cn . Prospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen M, Chen L, Yang Y, et al. Cipepofol for adjunctive sedation during neuraxial anesthesia: a study protocol for a randomized controlled trial. Trials. 2026. PMID: 42169054. doi:10.1186/s13063-026-09801-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。